Background: Identification of high-risk patients with multiple myeloma (MM) is important for improving treatment outcomes. Efforts to identify significant prognostic markers are unremitting. Angiogenesis plays an important mechanism in the progression of MM. One of the mediators of this angiogenic process is interleukin-10 (IL-10). Aim: To assess the role of IL-10 as a prognostic marker in MM. Methods: This was a cross-sectional study that included 39 newly diagnosed patients with MM. Serum IL-10 level was measured using Magnetic Luminex® Assay multiplex. The relationship between IL-10 and tumor stage and other known prognostic markers in MM was studied. Results: The median (interquartile range) value of IL-10 was 3 (2.9 -3.2) pg/mL. Interleukin-10 level differed significantly according to the revised International Staging System stage of MM, being higher in higher stages. The median (interquartile range) IL-10 level was 2.89 (2.79 -2.95) pg/mL in stage I, 3 (2.9 -3.1) in stage II and 3.2 (3.1 -3.66) in stage III (p = 0.0009). In addition, higher IL-10 significantly correlated with lower hemoglobin (p = 0.002), lower albumin (p = 0.045), higher creatinine (p = 0.009), higher β2-microglobulin (p = 0.002), higher lactate dehydrogenase (p = 0.0007) and higher bone marrow plasma cell percentage (p = 0.015).
Conclusion:The results support a prognostic role of IL-10 in MM and its pathogenesis.
Background
Locally advanced rectal cancer (LARC) has a high incidence of local and distant relapse even after adequate treatment. The emerging role of neoadjuvant induction chemotherapy may allow initial down staging of the primary tumor, less toxicity profile and early treatment of micrometastatic disease followed by chemoradiation, and optimum local control may be attained, with the hope of increased complete response rates
Objectives
to identify the effect of induction chemotherapy with oxaliplatin and capecitabine (CapeOx) before concurrent chemoradiation in locally advanced rectal cancer in terms of response and toxicity. Primary end point is assessment of complete pathological response rate.
Patient and Methods
patients with MRI based criteria of high-risk LARC (T4 tumors, tumors within 2 mm of mesorectal fascia, T3 tumors at or below levators and T2-4N+ve tumors) were included. Patients received 12 weeks of induction capecitabine/oxaliplatin followed by concomitant capecitabine and conventional three dimensional conformal radiotherapy. Surgery was done at least 6 weeks after CCRTH.
Results
Thirty five patients with LARC were recruited during the period from December 2017 till January 2019. Five patients (20.8%) had a pathological complete response (TRG 0) (ypT0N0). Another three patients (12.5%) had near complete pathological response (TRG 1). While unfortunately 29.2% and 37.5% had partial response and poor response respectively.
Conclusion
Induction chemotherapy could be a promising option for better response rates either clinical or pathological for high risk LARC patients with acceptable toxicity profile.
Conclusions: These results suggest that in this cohort of r/r patients, SPM IR increases with age and that most of the SPMs are solid tumours. To our knowledge, this is one of the first studies that uses real-world data to estimate a population-level background incidence for SPMs in r/r NHL and MM patients, regardless of therapy received.
Background: COPD is a great challenge as it is a main cause of morbidity and mortality around the world. COPD exacerbations increasing airway and systemic inflammation. Aim of this study: the study aimed to assess the role of MPV as a marker of inflammation in COPD patients and to evaluate its role as a prognosis parameter in AE COPD. Patients and Methods: This study was conducted at Zagazig University Hospitals, Chest Department, during the period from April 2017 till October 2017, the study included 25 stable and 25 exacerbated chronic obstructive pulmonary disease (COPD) patients, selected in non randomized manner. Results: showed that there was no significant statistical difference in RBCs, hemoglobin and hematocrit content and a highly statistical significant increase in white blood cells (WBCs) count, neutrophils count, while lymphocytes shows significant statistical increase among stable COPD group among studied groups. The results showed that the Validity of MPV cutoff value, Sensitivity was 76.0%, Specificity was 80.0%, +VE predictive was 79.1%, -VE predictive was 76.9% and the accuracy was 78.0%.Conclusion: MPV is an easily accessible low cost marker of inflammation in AECOPD. Decreased MPV values can be used as indicator for negative acute-phase reaction in the exacerbated COPD patients. Cut off-point of MPV<9.4 fl can be used as a threshold mean of bad outcome. Keywords; Mean Platelet volume, COPD exacebations, prognosis INTRODUCTION hronic Obstructive Pulmonary Disease (COPD) is a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive, associated with an abnormal inflammatory response of the lungs to noxious particles or gases and associated with systemic manifestations. [1] .COPD is a serious disease cause airflow obstruction. COPD also, associated with systemic inflammation such as blood leukocytes increase, inflammatory cytokines and C. reactive protein (CRP) [2] .The Mean platelet volume (MPV), blood count test which is important indicator the production rate of platelet and stimulation [3] .Many authors have reported that the increase in MPV can be considered as prognostic factor for pulmonary hypertension and thromboembolism in COPD patients. [4,5] However the association between Mean platelet Volume and Chronic Obstructive Pulmonary Disease is still controversial. Some authors reported that there were an C Mostafa I. et al….
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.